Reduced Dose of Abiraterone Acetate with Concomitant Low-dose Prednisone in the Treatment of ≥ 85 Year-old Patients with Advanced Castrate-resistant Prostate Cancer

Anticancer Res. 2015 May;35(5):3097-102.

Abstract

Aim: The aim of the study was to evaluate the activity and safety of reduced-dose abiraterone acetate (AA) in ≥ 85 year-old patients with advanced castrate-resistant prostate cancer (CRPC).

Patients and methods: Patients received 750 mg oral AA as three 250-mg tablets once daily, with concomitant oral prednisone, 5 mg daily.

Results: Twenty-six patients were enrolled; median age was 88 years (range=85-93). Prostate-specific antigen (PSA) response was observed in 18 (69.2%) subjects, median time to PSA progression was 6.4 months (95% confidence interval (CI)=2.8-8.8) and median overall survival was 14.3 months (95% CI=7.2-18.3). The treatment was well-tolerated and adverse events, related to mineralocorticoid excess, were of grade 1-2 in all patients.

Conclusion: Reduced dose of AA combined with a very low dose of prednisone is effective and well-tolerated in very elderly patients with advanced CRPC.

Keywords: Abiraterone; PSA; castrate-resistant; elderly; prostate cancer.

MeSH terms

  • Abiraterone Acetate
  • Aged, 80 and over
  • Androstenes / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Dose-Response Relationship, Drug
  • Humans
  • Male
  • Neoplasm Staging
  • Prednisone / administration & dosage*
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms, Castration-Resistant / blood
  • Prostatic Neoplasms, Castration-Resistant / drug therapy*
  • Prostatic Neoplasms, Castration-Resistant / mortality
  • Prostatic Neoplasms, Castration-Resistant / pathology

Substances

  • Androstenes
  • Prostate-Specific Antigen
  • Abiraterone Acetate
  • Prednisone